Display options
Cite
Devecchi A, De Cecco L, Dugo M, et al. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun (Lond). 2018;38(1):70doi: 10.1186/s40880-018-0339-3.
Devecchi, A., De Cecco, L., Dugo, M., Penso, D., Dagrada, G., Brich, S., Stacchiotti, S., Sensi, M., Canevari, S., & Pilotti, S. (2018). The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer communications (London, England), 38(1), 70. https://doi.org/10.1186/s40880-018-0339-3
Devecchi, Andrea, et al. "The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response." Cancer communications (London, England) vol. 38,1 (2018): 70. doi: https://doi.org/10.1186/s40880-018-0339-3
Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, Stacchiotti S, Sensi M, Canevari S, Pilotti S. The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response. Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3. PMID: 30486883; PMCID: PMC6260689.
Copy Download .nbib Format: NLM
Share it on

Cancer Commun (Lond). 2018 Nov 28;38(1):70. doi: 10.1186/s40880-018-0339-3.

The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial-mesenchymal transition, and immune response.

Cancer communications (London, England)

Andrea Devecchi, Loris De Cecco, Matteo Dugo, Donata Penso, Gianpaolo Dagrada, Silvia Brich, Silvia Stacchiotti, Marialuisa Sensi, Silvana Canevari, Silvana Pilotti

Affiliations

  1. Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 2133, Milan, Italy.
  2. Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133, Milan, Italy.
  3. Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133, Milan, Italy.
  4. Platform of Integrated Biology, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 2133, Milan, Italy. [email protected].
  5. Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133, Milan, Italy. [email protected].

PMID: 30486883 PMCID: PMC6260689 DOI: 10.1186/s40880-018-0339-3

Abstract

BACKGROUND: Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive, and poorly investigated simple sarcoma with a low frequency of genetic deregulation other than an Ewing sarcoma RNA binding protein 1 (EWSR1)-Wilm's tumor suppressor (WT1) translocation. We used whole-exome sequencing to interrogate six consecutive pre-treated DSRCTs whose gene expression was previously investigated.

METHODS: DNA libraries were prepared from formalin-fixed, paraffin-embedded archival tissue specimens following the Agilent SureSelectXT2 target enrichment protocol and sequenced on Illumina NextSeq 500. Raw sequence data were aligned to the reference genome with Burrows-Wheeler Aligner algorithm. Somatic mutations and copy number alterations (CNAs) were identified using MuTect2 and EXCAVATOR2, respectively. Biological functions associated with altered genes were investigated through Ingenuity Pathway Analysis (IPA) software.

RESULTS: A total of 137 unique somatic mutations were identified: 133 mutated genes were case-specific, and 2 were mutated in two cases but in different positions. Among the 135 mutated genes, 27% were related to two biological categories: DNA damage-response (DDR) network that was also identified through IPA and mesenchymal-epithelial reverse transition (MErT)/epithelial-mesenchymal transition (EMT) already demonstrated to be relevant in DSRCT. The mutated genes in the DDR network were involved in various steps of transcription and particularly affected pre-mRNA. Half of these genes encoded RNA-binding proteins or DNA/RNA-binding proteins, which were recently recognized as a new class of DDR players. CNAs in genes/gene families, involved in MErT/EMT and DDR, were recurrent across patients and mostly segregated in the MErT/EMT category. In addition, recurrent gains of regions in chromosome 1 involving many MErT/EMT gene families and loss of one arm or the entire chromosome 6 affecting relevant immune-regulatory genes were recorded.

CONCLUSIONS: The emerging picture is an extreme inter-tumor heterogeneity, characterized by the concurrent deregulation of the DDR and MErT/EMT dynamic and plastic programs that could favour genomic instability and explain the refractory DSRCT profile.

Keywords: Chromosome imbalance; Copy number alterations; DNA damage response; Desmoplastic small round cell tumor; Genomic stability; Immune response; Mesenchymal–epithelial reverse transition/epithelial–mesenchymal transition; Somatic mutations; Whole-exome sequencing

References

  1. Cancer Res. 2014 Aug 15;74(16):4526-35 - PubMed
  2. Sci Rep. 2016 Oct 20;6:35521 - PubMed
  3. Cell. 2012 Sep 14;150(6):1107-20 - PubMed
  4. Curr Opin Struct Biol. 2005 Jun;15(3):367-73 - PubMed
  5. Clin Sarcoma Res. 2013 Nov 26;3(1):14 - PubMed
  6. Sci Transl Med. 2016 Mar 2;8(328):328rv4 - PubMed
  7. FEBS Lett. 2008 Jun 18;582(14):1977-86 - PubMed
  8. Int J Clin Exp Pathol. 2015 Jan 01;8(1):973-82 - PubMed
  9. Mol Cell. 2016 Feb 18;61(4):496-505 - PubMed
  10. PLoS One. 2014 Aug 13;9(8):e93676 - PubMed
  11. RNA Biol. 2011 Sep-Oct;8(5):817-28 - PubMed
  12. Nucleic Acids Res. 2016 Nov 16;44(20):e154 - PubMed
  13. ScientificWorldJournal. 2010 Jul 20;10:1450-61 - PubMed
  14. Cell. 2017 Nov 30;171(6):1252-1253 - PubMed
  15. Oncotarget. 2017 May 16;8(20):32492-32504 - PubMed
  16. Nat Methods. 2014 Apr;11(4):361-2 - PubMed
  17. J Thorac Oncol. 2015 Mar;10(3):409-11 - PubMed
  18. Oncoscience. 2015 Feb 20;2(2):187-92 - PubMed
  19. J Clin Invest. 2016 Sep 1;126(9):3219-35 - PubMed
  20. Sci Rep. 2015 Sep 22;5:14262 - PubMed
  21. Genome Res. 2010 Sep;20(9):1297-303 - PubMed
  22. Clin Chem. 2015 Jan;61(1):64-71 - PubMed
  23. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  24. Am J Cancer Res. 2017 Jun 01;7(6):1389-1406 - PubMed
  25. Semin Cell Dev Biol. 2018 Jul;79:113-122 - PubMed
  26. Bioinformatics. 2009 Aug 15;25(16):2078-9 - PubMed
  27. RNA. 2011 Apr;17(4):665-74 - PubMed
  28. Genome Biol. 2016 Feb 22;17:31 - PubMed
  29. Curr Pharm Des. 2015;21(10):1292-300 - PubMed
  30. Clin Cancer Res. 2012 Nov 1;18(21):5837-44 - PubMed
  31. Nucleic Acids Res. 2011 Sep 1;39(17):e118 - PubMed
  32. Hum Genomics. 2016 Nov 18;10(1):36 - PubMed
  33. Nat Rev Cancer. 2011 Jul 14;11(8):541-57 - PubMed
  34. Hum Mutat. 2015 Apr;36(4):E2423-9 - PubMed
  35. J Mol Biol. 2017 Oct 27;429(21):3139-3145 - PubMed
  36. Int J Clin Exp Pathol. 2010 Apr 23;3(4):416-28 - PubMed
  37. Bioinformatics. 2016 Oct 15;32(20):3196-3198 - PubMed
  38. Oncotarget. 2016 Jul 12;7(45):72381-72394 - PubMed
  39. Trends Cancer. 2017 Jul;3(7):506-528 - PubMed
  40. Nat Protoc. 2009;4(7):1073-81 - PubMed
  41. Int J Mol Sci. 2017 Jun 23;18(7):null - PubMed
  42. Bioinformatics. 2009 Jul 15;25(14):1754-60 - PubMed
  43. Trends Biochem Sci. 2014 Mar;39(3):141-9 - PubMed
  44. Cell. 2017 Nov 2;171(4):950-965.e28 - PubMed
  45. Nucleic Acids Res. 2013 Apr 1;41(6):e67 - PubMed
  46. Nat Rev Mol Cell Biol. 2007 Jun;8(6):479-90 - PubMed
  47. Nat Biotechnol. 2013 Mar;31(3):213-9 - PubMed

MeSH terms

Publication Types